Navigation Links
Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
Date:5/12/2009

Pharma's Premier Quantitative Company and Drug Evaluation Tool Designed Specifically for Business Development Available Now with a New User-Friendly Interface

Productview Plus from Decision Resources Includes Data for Over 1000 Drugs Across 147 Product Classes

WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the growth in drug sales of the top 10 pharmaceutical companies slowed to its lowest level in years in 2008 -- growing just 3.7 percent compared to 7.9 percent the year before. The performance of the top 10 companies in the U.S. market, the world's largest, was particularly poor, with sales down 3.5 percent year-over-year.

"This trend is expected to continue in the U.S. with growth in the top 10 companies forecasted to remain flat out to 2015 despite the contribution of recently seen large-scale acquisitions by Pfizer, Roche and Merck & Co.," said Stephan Gauldie Ph.D., Director at Decision Resources. "Of the top 10 pharma companies, only Roche is expected to post a compound annual growth rate above the 3 percent that is forecasted for the overall U.S. market out to 2015."

These data come from the newly updated Productview Plus, the pharmaceutical industry's premier quantitative company and drug evaluation tool designed specifically for business development. The new Productview Plus allows business planners and new product commercialization managers to quickly assess forecasts and evaluate market scenarios that will determine a company's/drug's success or failure.

"By manipulating the data by brand, therapeutic area, drug class and company, users can track market sizes, assess barriers to market entry, quickly benchmark internal forecasts or analyze the potential of licensing candidates," continued Dr. Gauldie.

Based on company reported sales, Productview Plus includes data for 1,100 ethical drugs from over 110 companies and across 147 product classes. Productview Plus provides five years of historical sales as well as a seven-year forecast for all drugs, split by United States and Rest of World regions -- allowing users to get a universal understanding of a company's/drug's current and future position.

Productview Plus is available now from Decision Resources.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Elizabeth Marshall
    Decision Resources
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Actuaries: Addressing Health Spending Growth is Path to Sustainable Health Care System
2. Covance To Present at Bairds 2009 Growth Stock Conference
3. Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results
4. Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine
5. AMN Healthcare Services to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference and at the Robert W. Baird 2009 Growth Stock Conference
6. Adolescent Growth Plate Injuries May Be Related to Overuse
7. Despite the Economic Downturn, Long-Term Growth Potential in the US Dental Biomaterial Market Remains Robust
8. Process controlling T cell growth and production identified
9. Injured Marines at Risk for Abnormal Bone Growth
10. Injured Marines at risk for abnormal bone growth
11. Genoptix Reports Strong Growth for the First Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... ... 2017 , ... Boar’s Head Brand®, one of the nation’s ... entertaining that are sure to satisfy your guests’ flavor cravings, while adding delicious ... featured in these refreshingly balanced recipes are packed with flavor, creating the perfect ...
(Date:5/26/2017)... ... 2017 , ... Silver Birch of Hammond, a new assisted lifestyle community, has ... acres of land at 5620 Sohl Avenue in Hammond, serves older adults who need ... studio and one-bedroom apartments. Each of the private apartments at Silver Birch features a ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... recipient of proceeds from its 14th Annual Clays for Kids fundraiser, to be ... 30, Bennett, Colorado. , As part of BluSky’s partnership with The Adoption ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, ... most appropriate instruments for research and understanding the basic principles that were designed ... focus on innovations in stereo microscopy for brightfield and fluorescence typically used in ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... May 9, 2017  Demonstrating its commitment to ... directors for the Pharmaceutical Research and Manufacturers of ... Biopharmaceutical companies will now have to meet new ... be eligible to join PhRMA. "By ... is sending a clear message that being a ...
(Date:5/8/2017)... Mich. , May 8, 2017  Diplomat Pharmacy, ... WRB Communications, Inc. ("WRB"), a health care service ... . WRB specializes in relationship management programs ... WRB will join ... Diplomat,s commercialization support services for manufacturers, biotech firms, and ...
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" Fortuna ... be the first to eliminate the need for embryonic and ... to treat neurodegenerative diseases. Fortuna announced ... Professor Michael Fehlings , MD, PhD; Father Kevin ... MD, MPH; and Professor James Giordano , PhD. ...
Breaking Medicine Technology: